GIP (1–42) vs GLP-1 (7–36) amide

How they're alike

GIP and GLP-1 are the two endogenous incretin hormones in humans — gut peptides secreted in response to nutrient ingestion that amplify insulin release from pancreatic β-cells in a glucose-dependent manner (Seino 2010). Both act through class B (secretin-family) G-protein-coupled receptors — GIPR for GIP, GLP-1R for GLP-1 — whose activation couples to Gαs, raises intracellular cAMP in the β-cell, and potentiates glucose-stimulated insulin granule exocytosis (Seino 2010, Graaf 2016). Together, the two hormones account for a substantial share of post-meal insulin release: Salehi and colleagues (2010), using the GLP-1R antagonist exendin-(9–39) to quantify the endogenous contribution, noted that incretins (GLP-1 plus GIP) account for up to roughly 60% of post-prandial insulin secretion in healthy people. Both peptides also share the structural problem that has shaped their respective therapeutic stories — short native half-lives in circulation, which is why drug development in both classes has centred on engineered analogs and multi-receptor agonists rather than the native sequences themselves (Graaf 2016, Müller 2025).

How they differ

The two hormones are released from different enteroendocrine populations and have non-identical biology beyond the β-cell. GIP is produced by K-cells in the upper small intestine, while GLP-1 (7–36) amide is released by L-cells in the lower small intestine and colon, and GLP-1 is cleaved out of the larger proglucagon precursor by prohormone convertase 1/3 alongside GLP-2, oxyntomodulin, and glicentin (Lafferty 2021, Spreckley 2015). GLP-1's pancreatic and extra-pancreatic effects extend beyond insulin potentiation to include suppression of α-cell glucagon secretion, slowing of gastric emptying, and engagement of appetite-regulating circuits in the brain — the full package that makes GLP-1R agonists clinically useful for both glycaemia and body weight (Donnelly 2012, Farhadipour 2021). GIP's non-pancreatic biology — particularly its role in adipose tissue, bone, and the CNS — remains an active area in recent reviews rather than a settled picture (Bailey 2024, Müller 2025).

Pharmacological tooling around the two receptors also diverges. The most-used GIPR tool ligand, (Pro3)GIP, behaves as a competitive antagonist at rat and mouse GIPR but as a full agonist at human GIPR — a species mismatch that complicates extrapolation of rodent GIP-blockade results to human drug design (Sparre-Ulrich 2015). The relative physiological weight of the two incretins is also context-dependent: Gault and colleagues (2003) combined (Pro3)GIP with the GLP-1R antagonist exendin(9–39) in obese diabetic (ob/ob) mice and concluded that GIP was the major physiological incretin in that model — the opposite balance from what dominates the clinical GLP-1 literature in humans. The most consequential modern difference is translational. Native GLP-1 (7–36) amide directly inspired the GLP-1R agonist drug class — exenatide, liraglutide, semaglutide — engineered to resist DPP-4 cleavage and bind albumin for hours-to-days half-life (Graaf 2016). GIPR engagement in humans has, by contrast, advanced principally through tirzepatide, a dual GIP/GLP-1 receptor agonist that Willard and colleagues (2020) characterised as "imbalanced and biased," with non-equivalent occupancy and downstream signalling at the two receptors at clinically relevant exposures (Galindo 2026).

Head-to-head clinical evidence

No head-to-head clinical trial directly compares native GIP (1–42) and native GLP-1 (7–36) amide as therapeutics, because neither endogenous peptide is itself a marketed drug — both are used in human research as short infusions and as reference ligands for receptor pharmacology, not as chronic interventions (Donnelly 2012, Müller 2025). The closest direct comparison in the dossier is mechanistic rather than clinical: Gault and colleagues (2003) used the GIPR antagonist (Pro3)GIP and the GLP-1R antagonist exendin(9–39), alone and in combination, in ob/ob mice to apportion the postprandial insulin response between the two incretins, concluding that GIP was the dominant physiological incretin in that model. In humans, the comparator data are indirect — Kreymann and colleagues (1987) first established GLP-1 (7–36) as a physiological incretin in healthy volunteers, and Salehi and colleagues (2010) used exendin-(9–39) infusion in people with and without type 2 diabetes to show that endogenous GLP-1 contributes meaningfully to post-prandial insulin secretion in both groups. The translation of "GIP plus GLP-1" into a single molecule — tirzepatide — has produced clinical trial data attached to the engineered drug rather than to either endogenous peptide; mechanistic pharmacology of that dual agonist at the human GIPR and GLP-1R is reported by Willard and colleagues (2020).

Safety profile comparison

Because neither native peptide is administered as a chronic drug, neither carries an adverse-event profile of the kind compiled for marketed therapeutics. Short-duration human infusions of GLP-1 (7–36) amide are used as a research probe (Kreymann 1987, Salehi 2010), and synthetic GIP(1–42) is used as a tool peptide for in vitro and in vivo pharmacology (Sparre-Ulrich 2015, Gault 2003) — but no comparable randomised-trial safety dataset exists for either endogenous peptide given therapeutically. The clinical safety signal associated with sustained GIPR engagement in humans is captured indirectly via tirzepatide, where Zeng and colleagues (2023) carried out a systematic review and meta-analysis of randomised trials in type 2 diabetes and obesity to evaluate pancreatitis and gallbladder or biliary disease — that dataset is attached to the engineered dual agonist, not to either native incretin. One mechanistic safety-adjacent point favours both endogenous peptides: their action at the β-cell is glucose-dependent, so insulin secretion is amplified when blood glucose is elevated but not when it is low, a property carried forward into GLP-1R agonist drugs and one reason this class is associated with lower hypoglycaemia risk than insulinotropic sulphonylureas (Meloni 2013, Donnelly 2012).

Indication overview

Neither GIP (1–42) human nor GLP-1 (7–36) amide is itself a marketed therapeutic; both are endogenous hormones used in research as reference ligands and short-infusion probes (Donnelly 2012, Bailey 2024). The therapeutic value of the GLP-1 system in humans is captured almost entirely by engineered GLP-1R agonists — exenatide, liraglutide, semaglutide — that re-engineer the 30-residue endogenous peptide for resistance to DPP-4 and for prolonged circulation (Graaf 2016, Galindo 2026). The therapeutic value of the GIP system in humans is, at present, captured primarily by the dual GIP/GLP-1 receptor agonist tirzepatide rather than by any selective GIPR drug; recent reviews frame duodenal K-cells and GIPR as treatment targets for obesity and type 2 diabetes in their own right, while noting that the therapeutic logic of GIPR engagement — agonism versus antagonism — is still actively debated in the literature (Bailey 2024, Müller 2025, Willard 2020).